Moreover, high genetic alteration rate of DPM1/2/3 (41%) was also observed, and genetic alteration in DPM1/2/3 was associated with shorter OS in HCC patients, which provide a better understanding of molecular targets for improved liver cancer therapeutic strategies in the future. The gene discussed is DPM1; the disease is hepatocellular carcinoma.